@misc{10498/33108,
year = {2024},
url = {http://hdl.handle.net/10498/33108},
abstract = {Objective: Dose optimization plays a key role in determining clinical outcomes in patients on opioid agonist treatment (OAT). The objective of this study was to identify the variables independently associated with buprenorphine/naloxone (B/N) dose adequacy in patients with opiate use disorder (OUD). Method: Cross-sectional study of a convenience sample of patients with OUD treated with B/N (n = 315) in four regions in Spain. The Opiate Dosage Adequacy Scale (ODAS) was used to determine B/N dose adequacy. The ODAS evaluate the six components of the “dose adequacy” construct, as follows: continued use of heroin; narcotic blockade or crossed tolerance; objective opioid withdrawal symptoms (OWS); subjective OWS; craving for heroin; and overmedication. A binomial logistic regression analysis was performed to identify the variables associated with the condition “ODAS Adequate B/N dose”. Participants completed a battery of instruments to assess sociodemographic, substance use, clinical, and treatment variables. Results: The B/N dose was considered adequate in 231 of the 315 participants (73.3 %). Two variables, satisfaction with B/N as a medication (OR=5.764, 95 % CI=2.211-15.030) and patient-perceived participation in B/N dose decisions (OR=1.790, 95 % CI=1221-2623), were independently, significantly, and positively associated with the “ODAS Adequate B/N dose” condition. While the severity of heroin dependence was significantly associated with buprenorphine dose adequacy in the bivariate analyses, significance was lost in the full regression model.},
keywords = {Opioid dependence},
keywords = {Opioid agonist treatment},
keywords = {Buprenorphine},
keywords = {Dosing},
keywords = {Outcomes},
keywords = {Shared decision making},
title = {Assessing predictors of adequate individual buprenorphine maintenance dosage for the treatment of opioid use disorder: Listening to the patient},
doi = {10.1016/j.drugpo.2024.104519},
author = {González Saiz, Francisco Manuel and Vergara Moragues, Esperanza and Trujols, Joan and Alcaraz, Saul and Siñol, Núria and Pérez de los Cobos, José and Buprenorphine/Naloxone Survey},
}